Stryker (NYSE:SYK) Upgraded by BMO Capital Markets to “Strong-Buy” Rating

BMO Capital Markets upgraded shares of Stryker (NYSE:SYK) to a strong-buy rating in a research note published on Wednesday,Zacks.com reports.

Several other brokerages have also commented on SYK. Argus set a $370.00 price objective on Stryker in a report on Thursday. UBS Group cut their price objective on Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a report on Tuesday, March 17th. Truist Financial reaffirmed a “hold” rating and set a $330.00 target price (down from $380.00) on shares of Stryker in a report on Monday, May 4th. Weiss Ratings lowered Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. Finally, Barclays cut their price target on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a report on Monday, May 4th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $392.87.

Stryker Price Performance

SYK opened at $326.87 on Wednesday. The company has a market capitalization of $125.31 billion, a price-to-earnings ratio of 37.83, a PEG ratio of 2.09 and a beta of 0.77. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. Stryker has a 12-month low of $281.00 and a 12-month high of $404.87. The business’s fifty day simple moving average is $309.82 and its 200-day simple moving average is $338.02.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The business had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period last year, the firm earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities research analysts anticipate that Stryker will post 14.98 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio is 40.74%.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP M Kathryn Fink sold 3,500 shares of Stryker stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.45, for a total transaction of $992,075.00. Following the completion of the transaction, the vice president directly owned 177 shares of the company’s stock, valued at $50,170.65. The trade was a 95.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Stryker

A number of large investors have recently bought and sold shares of the business. VanderPol Investments L.L.C. grew its holdings in Stryker by 1.4% in the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock valued at $732,000 after purchasing an additional 28 shares during the period. KCM Investment Advisors LLC lifted its position in shares of Stryker by 1.5% during the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock valued at $653,000 after buying an additional 28 shares in the last quarter. Rossby Financial LCC lifted its position in shares of Stryker by 6.6% during the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock valued at $159,000 after buying an additional 28 shares in the last quarter. Tcfg Wealth Management LLC grew its stake in Stryker by 2.7% in the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock valued at $403,000 after acquiring an additional 29 shares during the period. Finally, Mechanics Financial Corp increased its holdings in Stryker by 1.2% in the 4th quarter. Mechanics Financial Corp now owns 2,458 shares of the medical technology company’s stock worth $864,000 after acquiring an additional 30 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.